Archives of Dermatological Research

, Volume 301, Issue 1, pp 83–86 | Cite as

Type I interferon-associated cytotoxic inflammation in cutaneous lupus erythematosus

  • Joerg Wenzel
  • Sabine Zahn
  • Thomas Bieber
  • Thomas Tüting


Inappropriate activation of innate immune mechanisms, in particular of the type I interferon (IFN) system, is regarded to play an important role in the pathogenesis of lupus erythematosus (LE). Type I IFN serum levels have been shown to correlate with the disease activity in systemic LE and additionally play a proinflammatory role in the development of LE skin lesions. Recent studies demonstrated a close morphological association between the expression pattern of IFN-inducible chemokines (MxA, CXCL10) and typical histological features of cutaneous LE. These and other studies suggest that a complex network of IFN-associated cytokines, chemokines and adhesion molecules orchestrates and promotes tissue injury observed in LE skin.


Skin Lupus CXCL9 CXCL10 CXCR3 


  1. 1.
    Adam C, Thoua Y, Ronco P et al (1980) The effect of exogenous interferon: acceleration of autoimmune and renal diseases in (NZB/W) F1 mice. Clin Exp Immunol 40:373–382PubMedGoogle Scholar
  2. 2.
    Arrue I, Saiz A, Ortiz-Romero PL et al (2007) Lupus-like reaction to interferon at the injection site: report of five cases. J Cutan Pathol 34(Suppl 1):18–21. doi:10.1111/j.1600-0560.2007.00715.x PubMedCrossRefGoogle Scholar
  3. 3.
    Asselin-Paturel C, Brizard G, Chemin K et al (2005) Type I interferon dependence of plasmacytoid dendritic cell activation and migration. J Exp Med 201:1157–1167. doi:10.1084/jem.20041930 PubMedCrossRefGoogle Scholar
  4. 4.
    Baechler EC, Batliwalla FM, Karypis G et al (2003) Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 100:2610–2615. doi:10.1073/pnas.0337679100 PubMedCrossRefGoogle Scholar
  5. 5.
    Bennett L, Palucka AK, Arce E et al (2003) Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 197:711–723. doi:10.1084/jem.20021553 PubMedCrossRefGoogle Scholar
  6. 6.
    Blomberg S, Eloranta ML, Cederblad B et al (2001) Presence of cutaneous interferon-alpha producing cells in patients with systemic lupus erythematosus. Lupus 10:484–490. doi:10.1191/096120301678416042 PubMedCrossRefGoogle Scholar
  7. 7.
    Braun D, Geraldes P, Demengeot J (2003) Type I Interferon controls the onset and severity of autoimmune manifestations in lpr mice. J Autoimmun 20:15–25. doi:10.1016/S0896-8411(02)00109-9 PubMedCrossRefGoogle Scholar
  8. 8.
    Clark-Lewis I, Mattioli I, Gong JH et al (2003) Structure–function relationship between the human chemokine receptor CXCR3 and its ligands. J Biol Chem 278:289–295. doi:10.1074/jbc.M209470200 PubMedCrossRefGoogle Scholar
  9. 9.
    Costedoat-Chalumeau N, Amoura Z, Hulot JS et al (2006) Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum 54:3284–3290. doi:10.1002/art.22156 PubMedCrossRefGoogle Scholar
  10. 10.
    Dall’era MC, Cardarelli PM, Preston BT et al (2005) Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis 64:1692–1697. doi:10.1136/ard.2004.033753 PubMedCrossRefGoogle Scholar
  11. 11.
    Fah J, Pavlovic J, Burg G (1995) Expression of MxA protein in inflammatory dermatoses. J Histochem Cytochem 43:47–52PubMedGoogle Scholar
  12. 12.
    Farkas L, Beiske K, Lund-Johansen F et al (2001) Plasmacytoid dendritic cells (natural interferon-alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 159:237–243PubMedGoogle Scholar
  13. 13.
    Graham RR, Kozyrev SV, Baechler EC et al (2006) A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 38:550–555. doi:10.1038/ng1782 PubMedCrossRefGoogle Scholar
  14. 14.
    Guillot B, Portales P, Du Thanh A et al (2005) The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon-alpha treatment. Br J Dermatol 152:690–696. doi:10.1111/j.1365-2133.2005.06512.x PubMedCrossRefGoogle Scholar
  15. 15.
    Hasegawa K, Hayashi T (2003) Synthetic CpG oligodeoxynucleotides accelerate the development of lupus nephritis during preactive phase in NZB x NZWF1 mice. Lupus 12:838–845. doi:10.1191/0961203303lu483oa PubMedCrossRefGoogle Scholar
  16. 16.
    Hooks JJ, Moutsopoulos HM, Geis SA et al (1979) Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 301:5–8PubMedGoogle Scholar
  17. 17.
    Iijima W, Ohtani H, Nakayama T et al (2003) Infiltrating CD8+ T cells in oral lichen planus predominantly express CCR5 and CXCR3 and carry respective chemokine ligands RANTES/CCL5 and IP-10/CXCL10 in their cytolytic granules: a potential self-recruiting mechanism. Am J Pathol 163:261–268PubMedGoogle Scholar
  18. 18.
    Kuhn A, Herrmann M, Kleber S et al (2006) Accumulation of apoptotic cells in the epidermis of patients with cutaneous lupus erythematosus after ultraviolet irradiation. Arthritis Rheum 54:939–950. doi:10.1002/art.21658 PubMedCrossRefGoogle Scholar
  19. 19.
    Kuhn A, Sonntag M, Lehmann P et al (2002) Characterization of the inflammatory infiltrate and expression of endothelial cell adhesion molecules in lupus erythematosus tumidus. Arch Dermatol Res 294:6–13. doi:10.1007/s00403-001-0286-7 PubMedCrossRefGoogle Scholar
  20. 20.
    Kuhn A, Sonntag M, Sunderkotter C et al (2002) Upregulation of epidermal surface molecule expression in primary and ultraviolet-induced lesions of lupus erythematosus tumidus. Br J Dermatol 146:801–809. doi:10.1046/j.1365-2133.2002.04693.x PubMedCrossRefGoogle Scholar
  21. 21.
    Lovgren T, Eloranta ML, Bave U et al (2004) Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum 50:1861–1872. doi:10.1002/art.20254 PubMedCrossRefGoogle Scholar
  22. 22.
    Lovgren T, Eloranta ML, Kastner B et al (2006) Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjogren’s syndrome autoantigen-associated RNA. Arthritis Rheum 54:1917–1927. doi:10.1002/art.21893 PubMedCrossRefGoogle Scholar
  23. 23.
    Meller S, Winterberg F, Gilliet M et al (2005) Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment: an amplification cycle triggering cutaneous lupus erythematosus. Arthritis Rheum 52:1504–1516. doi:10.1002/art.21034 PubMedCrossRefGoogle Scholar
  24. 24.
    Munoz LE, Gaipl US, Franz S et al (2005) SLE—a disease of clearance deficiency? Rheumatology (Oxford) 44:1101–1107. doi:10.1093/rheumatology/keh693 CrossRefGoogle Scholar
  25. 25.
    Nyberg F, Hasan T, Skoglund C et al (1999) Early events in ultraviolet light-induced skin lesions in lupus erythematosus: expression patterns of adhesion molecules ICAM-1, VCAM-1 and E-selectin. Acta Derm Venereol 79:431–436. doi:10.1080/000155599750009852 PubMedCrossRefGoogle Scholar
  26. 26.
    Nyberg F, Stephansson E (1999) Elevated soluble E-selectin in cutaneous lupus erythematosus. Adv Exp Med Biol 455:153–159PubMedGoogle Scholar
  27. 27.
    Rahman A, Isenberg DA (2008) Systemic lupus erythematosus. N Engl J Med 358:929–939. doi:10.1056/NEJMra071297 PubMedCrossRefGoogle Scholar
  28. 28.
    Ronnblom L, Eloranta ML, Alm GV (2006) The type I interferon system in systemic lupus erythematosus. Arthritis Rheum 54:408–420. doi:10.1002/art.21571 PubMedCrossRefGoogle Scholar
  29. 29.
    Santiago-Raber ML, Baccala R, Haraldsson KM et al (2003) Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 197:777–788. doi:10.1084/jem.20021996 PubMedCrossRefGoogle Scholar
  30. 30.
    Smit MJ, Verdijk P, van der Raaij-Helmer EM et al (2003) CXCR3-mediated chemotaxis of human T cells is regulated by a Gi- and phospholipase C-dependent pathway and not via activation of MEK/p44/p42 MAPK nor Akt/PI-3 kinase. Blood 102:1959–1965. doi:10.1182/blood-2002-12-3945 PubMedCrossRefGoogle Scholar
  31. 31.
    Sontheimer RD, Thomas JR, Gilliam JN (1979) Subacute cutaneous lupus erythematosus: a cutaneous marker for a distinct lupus erythematosus subset. Arch Dermatol 115:1409–1415. doi:10.1001/archderm.115.12.1409 PubMedCrossRefGoogle Scholar
  32. 32.
    Tebbe B, Mazur L, Stadler R et al (1995) Immunohistochemical analysis of chronic discoid and subacute cutaneous lupus erythematosus—relation to immunopathological mechanisms. Br J Dermatol 132:25–31. doi:10.1111/j.1365-2133.1995.tb08620.x PubMedCrossRefGoogle Scholar
  33. 33.
    Wenzel J, Henze S, Brahler S et al (2005) The expression of human leukocyte antigen-DR and CD25 on circulating T cells in cutaneous lupus erythematosus and correlation with disease activity. Exp Dermatol 14:454–459. doi:10.1111/j.0906-6705.2005.00301.x PubMedCrossRefGoogle Scholar
  34. 34.
    Wenzel J, Henze S, Wörrenkämper E et al (2005) Role of the chemokine receptor CCR4 and its ligand TARC/CCL17 for lymphocyte recruitment in cutaneous lupus erythematosus. J Invest Dermatol 124:1241–1248. doi:10.1111/j.0022-202X.2005.23755.x PubMedCrossRefGoogle Scholar
  35. 35.
    Wenzel J, Tuting T (2008) An IFN-associated cytotoxic cellular immune response against viral, self-, or tumor antigens is a common pathogenetic feature in “interface dermatitis”. J Invest Dermatol (in press), 17 April 2008 [Epub ahead of print]Google Scholar
  36. 36.
    Wenzel J, Tuting T (2007) Identification of type I interferon-associated inflammation in the pathogenesis of cutaneous lupus erythematosus opens up options for novel therapeutic approaches. Exp Dermatol 16:454–463. doi:10.1111/j.1600-0625.2007.00556.x PubMedCrossRefGoogle Scholar
  37. 37.
    Wenzel J, Uerlich M, Worrenkamper E et al (2005) Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA. Br J Dermatol 153:1011–1015. doi:10.1111/j.1365-2133.2005.06784.x PubMedCrossRefGoogle Scholar
  38. 38.
    Wenzel J, Worenkamper E, Freutel S et al (2005) Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus. J Pathol 205:435–442. doi:10.1002/path.1721 PubMedCrossRefGoogle Scholar
  39. 39.
    Wenzel J, Zahn S, Mikus S et al (2007) The expression pattern of interferon-inducible proteins reflects the characteristic histological distribution of infiltrating immune cells in different cutaneous lupus erythematosus subsets. Br J Dermatol 157:752–757. doi:10.1111/j.1365-2133.2007.08137.x PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Joerg Wenzel
    • 1
  • Sabine Zahn
    • 1
  • Thomas Bieber
    • 1
  • Thomas Tüting
    • 1
  1. 1.Department of DermatologyUniversity of BonnBonnGermany

Personalised recommendations